MARKET

ARVN

ARVN

Arvinas
NASDAQ
10.18
+0.08
+0.79%
After Hours: 10.18 0 0.00% 17:13 03/30 EDT
OPEN
10.11
PREV CLOSE
10.10
HIGH
10.33
LOW
10.00
VOLUME
633.16K
TURNOVER
--
52 WEEK HIGH
14.51
52 WEEK LOW
5.90
MARKET CAP
651.12M
P/E (TTM)
-8.9330
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0323-0327)?
Weekly Report · 21h ago
Weekly Report: what happened at ARVN last week (0316-0320)?
Weekly Report · 03/23 09:19
Top Executive’s Surprise Stock Move Shakes Up Arvinas Holding Company
TipRanks · 03/20 02:06
Arvinas Is Maintained at Buy by Citigroup
Dow Jones · 03/19 15:39
Arvinas Price Target Raised to $21.00/Share From $18.00 by Citigroup
Dow Jones · 03/19 15:39
Citigroup Maintains Buy on Arvinas, Raises Price Target to $21
Benzinga · 03/19 15:29
Arvinas Price Target Raised to $16.00/Share From $14.00 by BTIG
Dow Jones · 03/19 13:01
Arvinas Is Maintained at Buy by BTIG
Dow Jones · 03/19 13:01
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.